RNS Number : 6462C
Kromek Group PLC
30 April 2026

30 April 2026

Kromek Group plc
("Kromek", the "Company" or the "Group")

Issue of Equity, Total Voting Rights and Extension of Options

Kromek (AIM: KMK), a global detection company delivering best-in-class solutions for the advanced imaging and CBRN detection markets, announces that it has issued and allotted 40,000 ordinary shares of 1p each in the Company ("Ordinary Shares") following the exercise of options by a former employee who retired from the Company and is classified as a good leaver.

The Company also announces that it has agreed to extend the exercise period of certain share options granted to Berry Beumer, an Executive Director of the Company, as follows:

Director	Number of options	Exercise price	Grant date	Original expiry date	New expiry date
Berry Beumer	150,000	1.0p	29 April 2021	30 April 2026	31 May 2026

The extension was granted due to the original expiry date coinciding with a close period and the PDMR status of Mr Beumer would prevent him from potentially exercising these options.

Total voting rights

Application has been made to the London Stock Exchange for the 40,000 Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective at 8 a.m. on or around 7 May 2026. The new Ordinary Shares will rank pari passu with the existing Ordinary Shares in the Company.

Following Admission, the total number of Ordinary Shares in issue will be 655,136,840. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the Financial Conduct Authority's Disclosure Guidance and Transparency Rules.

Enquiries

Kromek Group plc
Arnab Basu, CEO — +44 (0)1740 626 060
Claire Burgess, CFO

Cavendish Capital Markets Limited (Nominated Adviser and Broker)
Geoff Nash/Giles Balleny/Seamus Fricker - Corporate Finance — +44 (0)20 7220 0500
Andrew Burdis - ECM
Michael Johnson - Sales

Gracechurch Group (Financial PR)
Harry Chathli/Claire Norbury — +44 (0)20 4582 3500

Kromek Group plc

Kromek Group plc is a leading developer of radiation detection and bio-detection technology solutions for the advanced imaging and CBRN detection segments. Headquartered in County Durham, UK, Kromek has manufacturing operations in the UK and US, delivering on the vision of enhancing the quality of life through innovative detection technology solutions.

The advanced imaging segment comprises the medical (including CT and SPECT), security and industrial markets. Kromek provides its OEM customers with detector components, based on its core cadmium zinc telluride (CZT) platform, to enable better detection of diseases such as cancer and Alzheimer's, contamination in industrial manufacture and explosives in aviation settings.

In CBRN detection, the Group provides nuclear radiation detection solutions to the global homeland defence and security market. Kromek's compact, handheld, high-performance radiation detectors, based on advanced scintillation and solid-state readout technology, are primarily used to protect critical infrastructure, events, personnel and urban environments from the threat of 'dirty bombs'.

The Group is also developing bio-security solutions in the CBRN detection segment. These consist of fully automated and autonomous systems to detect a wide range of airborne pathogens.

Kromek is listed on AIM, a market of the London Stock Exchange, under the trading symbol 'KMK'.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCIMMJTMTTJBFF